Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer’s disease and other neurodegenerative diseases

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Espert Review of Proteomics

• Publication date

  2017-03-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14789450.2017.1304217PMID 28281838
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer’s disease

  2017cited by this paper
• Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.

  2017cited by this paper
• A Precision Medicine Initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling

  2017cited by this paper
• Alzheimer's disease

  2016cited by this paper
• The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease

  2016cited by this paper
• How neuroinflammation contributes to neurodegeneration

  2016cited by this paper
• PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease.

  2016cited by this paper
• YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.

  2016cited by this paper
• Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington’s Disease

  2016cited by this paper
• Targeting innate immunity for neurodegenerative disorders of the central nervous system

  2016cited by this paper
• Neuroinflammation in Alzheimer's disease: Current evidence and future directions

  2016cited by this paper
• CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD.

  2016influential reference
• Application of Systems Theory in Longitudinal Studies on the Origin and Progression of Alzheimer's Disease.

  2016cited by this paper
• Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics

  2016cited by this paper
• Cerebrospinal Fluid Markers of Alzheimer’s Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer’s Disease

  2016influential reference
• CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.

  2016cited by this paper
• Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

  2016cited by this paper
• Biomarker-guided classification scheme of neurodegenerative diseases

  2016cited by this paper
• Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease

  2016influential reference
• Toward precision medicine in Alzheimer's disease.

  2016cited by this paper
• TSPO imaging in parkinsonian disorders

  2016influential reference
• Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease.

  2015influential reference
• Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis

  2015cited by this paper
• Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis

  2015cited by this paper
• The genetic landscape of Alzheimer disease: clinical implications and perspectives

  2015cited by this paper
• Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulation

  2015cited by this paper
• Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.

  2015cited by this paper
• Neuroinflammation in Alzheimer's disease.

  2015cited by this paper
• Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions

  2015cited by this paper
• Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort

  2015influential reference
• Immune attack: the role of inflammation in Alzheimer disease

  2015cited by this paper
• A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes

  2015influential reference
• The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies

  2015cited by this paper
• The choreography of neuroinflammation in Huntington's disease.

  2015cited by this paper
• Elevated Plasma YKL-40, Lipids and Lipoproteins, and Ischemic Vascular Disease in the General Population

  2015cited by this paper
• Dissecting IWG-2 typical and atypical Alzheimer’s disease: insights from cerebrospinal fluid analysis

  2015cited by this paper
• Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease

  2015cited by this paper
• Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease

  2015influential reference
• Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.

  2015cited by this paper
• Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging

  2015influential reference
• Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease

  2015cited by this paper
• Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias

  2015influential reference
• α-Synucleinopathy phenotypes.

  2014cited by this paper
• Neuronal and Glia-Related Biomarkers in Cerebrospinal Fluid of Patients with Acute Ischemic Stroke

  2014cited by this paper
• YKL-40 in cerebrospinal fluid in Huntington's disease--a role in pathology or a nonspecific response to inflammation?

  2014cited by this paper
• Relationship Between β-Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease

  2014influential reference
• Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study.

  2014cited by this paper
• Cerebrospinal Fluid Level of YKL-40 Protein in Preclinical and Prodromal Alzheimer's Disease

  2014influential reference
• Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions

  2014influential reference
• Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics

  2014cited by this paper
• Innate immune activation in neurodegenerative disease

  2014cited by this paper
• Microglial dysfunction in brain aging and Alzheimer's disease.

  2014cited by this paper
• Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

  2014cited by this paper
• Review - Part of the Special Issue: Alzheimer's Disease - Amyloid, Tau and Beyond Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers

  2014cited by this paper
• Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease

  2014influential reference
• CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment.

  2014cited by this paper
• The glial marker YKL‐40 is decreased in synucleinopathies

  2013influential reference
• Diabetes and risk of Parkinson's disease

  2013cited by this paper
• SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy.

  2013cited by this paper
• neurodegeneration : evidence for association of the p . R 47 H variant with frontotemporal dementia and Parkinson ¿ s disease Permalink

  2013influential reference
• Genetic insights in Alzheimer's disease.

  2013cited by this paper
• Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease

  2013cited by this paper
• Diverse pathological implications of YKL-40: answers may lie in 'outside-in' signaling.

  2013cited by this paper
• YKL-40 levels and atrial fibrillation in the general population.

  2013cited by this paper
• Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration

  2013cited by this paper
• Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease

  2012influential reference
• Serum YKL-40 Levels Correlate with Infarct Volume, Stroke Severity, and Functional Outcome in Acute Ischemic Stroke Patients

  2012cited by this paper
• Association between human cartilage glycoprotein 39 (YKL-40) and arterial stiffness in essential hypertension

  2012cited by this paper
• Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

  2012cited by this paper
• National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

  2012cited by this paper
• Characterization of the Fungal Microbiota (Mycobiome) in Healthy and Dandruff-Afflicted Human Scalps

  2012cited by this paper
• Variations of CHI3L1, Levels of the Encoded Glycoprotein YKL-40 and Prediction of Fatal and Non-fatal Ischemic Stroke

  2012cited by this paper
• Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia

  2012influential reference
• Astrocyte and Macrophage Regulation of YKL‐40 Expression and Cellular Response in Neuroinflammation

  2012cited by this paper
• Microglial activation in healthy aging.

  2012cited by this paper
• Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot

  2012cited by this paper
• Translational biomarker discovery in clinical metabolomics: an introductory tutorial

  2012cited by this paper
• Molecular Imaging of Microglial Activation in Amyotrophic Lateral Sclerosis

  2012influential reference
• Caspase signalling controls microglia activation and neurotoxicity

  2011cited by this paper
• Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease

  2011cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease.

  2011cited by this paper
• Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury.

  2011cited by this paper
• Neurovascular dysfunction, inflammation and endothelial activation: Implications for the pathogenesis of Alzheimer's disease

  2011cited by this paper
• Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders

  2011cited by this paper
• O3‐06‐06: The Projected impact of risk factor reduction on Alzheimer's disease prevalence

  2011cited by this paper
• Interferon regulatory factor 3-CL, an isoform of IRF3, antagonizes activity of IRF3

  2011cited by this paper
• Plasma level of chitinase 3-like 1 protein increases in patients with early Alzheimer’s disease

  2011cited by this paper
• Complement in the brain.

  2011cited by this paper
• Cerebrospinal Fluid Microglial Markers in Alzheimer’s Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility

  2011influential reference
• The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Extended results of the Alzheimer's disease anti‐inflammatory prevention trial

  2011cited by this paper
• Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Diabetes and Risk of Parkinson’s Disease

  2011cited by this paper
• Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

  2011cited by this paper
• YKL-40 Expression in Traumatic Brain Injury: An Initial Analysis

  2010cited by this paper
• Revising the definition of Alzheimer's disease: a new lexicon.

  2010cited by this paper
• Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis.

  2010cited by this paper
• In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases

  2010cited by this paper

• A nomogram based on serum CHI3L1 for predicting IVIG nonresponse in children with Kawasaki disease

  2026cites this paper
• Current potential biomarkers for Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis: review of literature

  2026cites this paper
• Roles of neuroimaging markers and biomarkers in cerebral small vessel disease and their associations with cognitive function

  2025cites this paper
• Biomarkers on anti-N-methyl-D-aspartate receptor encephalitis

  2025cites this paper
• The emerging role of chitinase-3-like-1 protein in neurodegeneration

  2025cites this paper
• Panel of Plasma Protein Biomarkers for Diagnosing Chronic Traumatic Encephalopathy in Adults

  2025cites this paper
• Rapid decline of cerebrospinal fluid biomarkers of axonal injury and neuroinflammation after initiation of antiretroviral therapy in HIV

  2025cites this paper
• APOE ε4 potentiates tau related reactive astrogliosis assessed by cerebrospinal fluid YKL40 in Alzheimer’s disease

  2025cites this paper
• Proteome-Based Biomarkers for Alzheimer’s Disease: Old Acquisitions and Innovative Proposals

  2025cites this paper
• From Amyloid to Synaptic Dysfunction: Biomarker-Driven Insights into Alzheimer’s Disease

  2025cites this paper
• Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications

  2025cites this paper
• Exercise to Counteract Alzheimer’s Disease: What Do Fluid Biomarkers Say?

  2024cites this paper
• Neuroinflammatory Biomarkers in Alzheimer’s Disease: From Pathophysiology to Clinical Implications

  2024cites this paper
• More than microglia: myeloid cells and biomarkers in neurodegeneration

  2024cites this paper
• Mitigating Neuroinflammation in Cognitive Areas: Exploring the Impact of HMG-CoA Reductase Inhibitor.

  2024cites this paper
• Primate cerebrospinal fluid CHI3L1 reflects brain TREM2 agonism

  2024cites this paper
• Tracking neuroinflammatory biomarkers in Alzheimer’s disease: a strategy for individualized therapeutic approaches?

  2024influential citation
• CHI3L1 as a Prognostic Biomarker and Therapeutic Target in Glioma

  2024cites this paper
• Inflammation and Huntington’s disease – a neglected therapeutic target?

  2024cites this paper
• Astrocyte-derived CHI3L1 signaling impairs neurogenesis and cognition in the demyelinated hippocampus.

  2024cites this paper
• Biofluid biomarkers for Alzheimer’s disease

  2024cites this paper
• Advances in Proteomics Research in Postoperative Delirium

  2024cites this paper
• Neurosyphilis is characterized by a compartmentalized and robust neuroimmune response but not by neuronal injury.

  2024cites this paper
• Divergent Cytokine and Chemokine Responses at Early Acute Simian Immunodeficiency Virus Infection Correlated with Virus Replication and CD4 T Cell Loss in a Rhesus Macaque Model

  2023cites this paper
• Preliminary Data on the Interactions Between Dementia and Some Metabolic Disfunctions

  2023cites this paper
• Neuroinflammation, Its Role in Alzheimer’s Disease and Therapeutic Strategies

  2023cites this paper
• Peripheral Blood and Cerebrospinal Fluid Levels of YKL-40 in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

  2023cites this paper
• Analyzing the glial proteome in Alzheimer’s disease

  2023cites this paper
• Astrocyte biomarkers GFAP and YKL‐40 mediate early Alzheimer's disease progression

  2023cites this paper
• Gene network analysis of the hypothalamus of rhesus macaques in different ages

  2023cites this paper
• Frailty is related to serum inflammageing markers: results from the VITAL study

  2023cites this paper
• Postoperative serum CHI3L1 level is associated with postoperative cognitive dysfunction in elderly patients after hip fracture surgery: A prospective observational study

  2023cites this paper
• Truncated TDP‐43 proteoforms diagnostic of frontotemporal dementia with TDP‐43 pathology

  2023cites this paper
• Alzheimer’s Disease and Neurosyphilis: Meaningful Commonalities and Differences of Clinical Phenotype and Pathophysiological Biomarkers

  2023cites this paper
• Astrocytic Chitinase‐3‐like protein 1 in neurological diseases: Potential roles and future perspectives

  2023cites this paper
• Molecules of senescent glial cells differentiate Alzheimer’s disease from ageing

  2023cites this paper
• Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology.

  2023cites this paper
• YKL-40 as a Novel Biomarker Related to White Matter Damage and Cognitive Impairment in Patients with Cerebral Small Vessel Disease.

  2023cites this paper
• Multi‐omic landscaping of human midbrains identifies disease‐relevant molecular targets and pathways in advanced‐stage Parkinson's disease

  2022cites this paper
• Identification of hub proteins in cerebrospinal fluid as potential biomarkers of Alzheimer’s disease by integrated bioinformatics

  2022cites this paper
• Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease

  2022cites this paper
• A Novel Panel of Plasma Proteins Predicts Progression in Prodromal Alzheimer’s Disease

  2022cites this paper
• Stress-Induced Depression and Alzheimer’s Disease: Focus on Astrocytes

  2022cites this paper
• Fluid Biomarkers in Alzheimer’s Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments

  2022cites this paper
• Current Insights on Neurodegeneration by the Italian Proteomics Community

  2022cites this paper
• Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis

  2022cites this paper
• Deep proteome analysis of plasma reveals novel biomarkers of mild cognitive impairment and Alzheimer’s disease: A longitudinal study

  2022cites this paper
• Identification of Serum Biomarkers in Patients with Alzheimer’s Disease by 2D-DIGE Proteomics

  2022cites this paper
• YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease

  2021cites this paper
• Potential Role of CHI3L1+ Astrocytes in Progression in MS

  2021cites this paper
• Proteomics for Target Identification in Psychiatric and Neurodegenerative Disorders.

  2021cites this paper
• Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges

  2021cites this paper
• Calcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis

  2021cites this paper
• Multi-omic landscaping of human midbrains identifies neuroinflammation as major disease mechanism in advanced-stage Parkinson's disease

  2021cites this paper
• Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease

  2021cites this paper
• Biomarkers and Their Implications in Alzheimer’s Disease: A Literature Review

  2021cites this paper
• Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy

  2021cites this paper
• Guillain–Barré Syndrome in COVID-19—The Potential Role of NCAM-1 and Immunotherapy

  2021cites this paper
• Biosensor approaches on the diagnosis of neurodegenerative diseases: Sensing the past to the future.

  2021cites this paper
• Neurodegeneration and Glial Activation Related CSF Biomarker as the Diagnosis of Alzheimer's Disease: A Systematic Review and an Updated Meta-analysis.

  2021cites this paper
• Identification of Plasma Proteome Signatures Associated With g SOMAscan

  2021cites this paper
• Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults.

  2020cites this paper
• Biomarkers: Our Path Towards a Cure for Alzheimer Disease

  2020cites this paper
• Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis

  2020cites this paper
• Fluid Candidate Biomarkers for Alzheimer’s Disease: A Precision Medicine Approach

  2020cites this paper
• Use of cerebrospinal fluid in diagnosis of dementia

  2020cites this paper
• Chitinase-3 like-protein-1 function and its role in diseases

  2020cites this paper
• Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers.

  2020cites this paper
• Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease

  2020cites this paper
• Optical coherence tomography-based assessment of retinal vascular pathology in cerebral small vessel disease

  2020cites this paper
• Future avenues for Alzheimer's disease detection and therapy: Liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery.

  2020cites this paper
• Clinical significance of fluid biomarkers in Alzheimer’s Disease

  2020cites this paper
• Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype

  2020cites this paper
• Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?

  2020cites this paper
• A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease

  2020cites this paper
• Aging-associated genes TNFRSF12A and CHI3L1 contribute to thyroid cancer: An evidence for the involvement of hypoxia as a driver

  2020cites this paper
• Metabolic alterations in the outer membrane vesicles of patients with Alzheimer's disease: an LC-MS/MS -based metabolomics analysis.

  2019cites this paper
• Alzheimer’s Disease and Artificial Intelligence: Long-term Personalized Rehabilitation and Medical and Social Support

  2019cites this paper
• Association of brain network dynamics with plasma biomarkers in subjective memory complainers.

  2019cites this paper
• Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer's disease.

  2019cites this paper
• Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial.

  2019cites this paper
• Biomarker-guided clustering of Alzheimer's disease clinical syndromes.

  2019cites this paper
• Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

  2019cites this paper
• Rapid Identification of Tanshinone IIA Metabolites in an Amyloid-β1-42 Induced Alzherimer’s Disease Rat Model using UHPLC-Q-Exactive Qrbitrap Mass Spectrometry

  2019cites this paper
• Elevated CHI3L1 and OPN levels in patients with anti-N-methyl-d-aspartate receptor encephalitis.

  2019cites this paper
• The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development

  2019influential citation
• Identification of Plasma Proteome Signatures Associated With Surgery Using SOMAscan.

  2019cites this paper
• Fluid and imaging biomarkers for Huntington's disease.

  2019cites this paper
• Alzheimer's disease biomarker‐guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1–42, total‐tau, phosphorylated‐tau, NFL, neurogranin, and YKL‐40

  2018influential citation
• CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers

  2018cites this paper
• Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology

  2018cites this paper
• The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer’s disease

  2018cites this paper
• Precision pharmacology for Alzheimer's disease.

  2018cites this paper
• Cerebrospinal fluid peptidomics: discovery of endogenous peptides as biomarkers of Alzheimer's disease

  2018cites this paper
• Current state of Alzheimer’s fluid biomarkers

  2018cites this paper
• Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic

  2018cites this paper
• Blood-based biomarkers for Alzheimer’s disease: mapping the road to the clinic

  2018cites this paper
• Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification.

  2018cites this paper
• From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer’s Disease

  2018cites this paper
• Analysis of macrophage production and biological activity of chitinase-like protein YKL-39

  2017cites this paper